FlexWave-Studie: Wirksamkeit der extrakorporalen Stoßwellentherapie bei Spastik der oberen Extremitäten nach einem Schlaganfall
Auswirkungen der extrakorporalen Stoßwelle auf die Spastik der oberen Gliedmaßenbeuger bei Schlaganfallpatienten: Eine randomisierte kontrollierte Studie
Extracorporeal shock wave therapy (ESWT) has emerged as an effective therapeutic intervention for addressing post-stroke limb spasticity. This research aims to explore the therapeutic implications of focused ESWT for wrist and finger flexor muscles in patients suffering from post-stroke upper limb spasticity.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
This study aimed to evaluate the effects of focused Extracorporeal Shock Wave Therapy (ESWT) on upper limb flexor spasticity in stroke patients. Participants were randomized into two groups: an experimental group receiving targeted ESWT on specific forearm flexor muscles, and a control group receiving placebo treatments mimicking the shockwave therapy, with treatments administered twice weekly over two weeks for a total of four sessions.
The efficacy of the treatment was measured using a comprehensive set of assessment tools, including range of motion, hand grip strength, pain levels, spasticity scales, functional assessments, as well as measures of daily living activities, ultrasound strain elastography. The outcomes were evaluated at multiple points in time: before treatment, and 1, 4, 12, and 24 weeks after the therapy concluded, to assess both immediate and sustained effects of the treatment on upper limb function and spasticity in stroke survivors.
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
-
Taipei, Taiwan, 100
- Department of Physical Medicine & Rehabilitation , National Taiwan University Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Individuals aged 18 years or older with unilateral cerebral stroke.
- Wrist/finger flexor muscle tone with a score greater than 1 on the Modified Ashworth Scale.
- Stable medical condition and vital signs.
- Conscious and able to comply with instructions.
Exclusion Criteria:
- History of more than one stroke, traumatic brain injury, or cerebral neoplasm.
- Coexisting central nervous system disorders (e.g., spinal cord injury, Parkinson's disease) or other musculoskeletal diseases affecting muscle tone assessment.
- Contraindications for shockwave intervention, such as malignancies, coagulopathies, local infections, or use of cardiac pacemakers.
- Undergone shockwave therapy or botulinum toxin injections for post-stroke spasticity in the past three months.
- Cognitive, consciousness, or language impairments preventing participation in the intervention or functional assessments.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Verdreifachen
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Focused Extracorporeal Shock Wave Therapy
Participants in this arm will receive focused Extracorporeal Shock Wave Therapy (ESWT) targeting three specific muscles: the flexor carpi ulnaris, flexor carpi radialis, and flexor digitorum superficialis. Each muscle will receive 1,500 shockwave shots per session, accumulating to a total of 4,500 shots across all targeted muscles in each session. The treatment will be administered twice a week for two consecutive weeks, resulting in a total of four treatment sessions. |
The focused shockwaves are directed at the affected muscles in the upper limb, specifically targeting the flexor carpi ulnaris, flexor carpi radialis, and flexor digitorum superficialis. |
|
Placebo-Komparator: Placebo-Controlled Shockwave Therapy
Participants in this arm will receive placebo-controlled focused ESWT, mirroring the treatment protocol of the experimental group but without the application of active shockwaves. |
The focused shockwaves are directed at the affected muscles in the upper limb, specifically targeting the flexor carpi ulnaris, flexor carpi radialis, and flexor digitorum superficialis. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
modified Ashworth scale (MAS)
Zeitfenster: pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
Evaluate spasticity in individuals with neurological conditions. The scale ranges from 0, indicating no increase in muscle tone, to 4, which represents severe spasticity with affected parts rigid in flexion or extension. |
pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
modified Tardieu scale (MTS) R2-R1 Angle
Zeitfenster: pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
Difference between passive range of motion (R2) and the angle of muscle catch (R1), measured in degrees. Larger values indicate greater dynamic spasticity. |
pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
|
Tardieu grade
Zeitfenster: pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
Spasticity severity (0-5); higher grades indicate greater spasticity. |
pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
|
passive range of motion for the wrist and finger joints
Zeitfenster: pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
the extent to which a joint can be moved without the patient actively participating in the movement |
pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
|
Medical Research Council (MRC) scale
Zeitfenster: pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
grades voluntary muscle strength on a 0-5 ordinal scale |
pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
|
hand grip strength
Zeitfenster: pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
use dynamometer to record the maximum force applied when the patient squeezes it |
pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
|
Barthel index
Zeitfenster: pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
measures a person's daily living abilities, focusing on ten areas of self-care and mobility. Scores range from 0 to 100, with higher scores denoting greater independence. |
pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
|
Functional Independence Measure (FIM)
Zeitfenster: pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
assesses a patient's level of disability and tracks changes over time, with a focus on physical and cognitive functioning across 18 items, scored from 18 (total assistance required) to 126 (fully independent). |
pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
|
Wolf Motor Function Test (WMFT) Functional ability score
Zeitfenster: pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
assess upper extremity function in individuals with neurological impairments, using 15 functional tasks. Scoring is on a 6-point ordinal scale, ranging from 0 ("Does not attempt with upper extremity being tested," indicating severe impairment) to 5 ("Movement appears to be normal," suggesting full functionality). Lower scores indicate greater impairment. |
pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
|
Action Research Arm Test (ARAT)
Zeitfenster: pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
a standardized measure evaluating upper limb motor ability in stroke patients, scoring from 0 (no movement) to 57 (normal arm function). It assesses grasp, grip, pinch, and gross arm movement. |
pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
|
Fugl-Meyer Assessment for the Upper Extremity (FMA-UE)
Zeitfenster: pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
range from 0 (complete paralysis) to 66 (full function), assessing motor recovery in post-stroke upper extremities |
pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
|
ultrasound assessment
Zeitfenster: pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
used strain elastography to assess elasticity of forearm muscles |
pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Hauptermittler: Shu-mei Yang, MD, National Taiwan University Hospital
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Dymarek R, Taradaj J, Rosinczuk J. Extracorporeal Shock Wave Stimulation as Alternative Treatment Modality for Wrist and Fingers Spasticity in Poststroke Patients: A Prospective, Open-Label, Preliminary Clinical Trial. Evid Based Complement Alternat Med. 2016;2016:4648101. doi: 10.1155/2016/4648101. Epub 2016 Jul 18.
- Cabanas-Valdes R, Calvo-Sanz J, Urrutia G, Serra-Llobet P, Perez-Bellmunt A, German-Romero A. The effectiveness of extracorporeal shock wave therapy to reduce lower limb spasticity in stroke patients: a systematic review and meta-analysis. Top Stroke Rehabil. 2020 Mar;27(2):137-157. doi: 10.1080/10749357.2019.1654242. Epub 2019 Nov 11.
- Yasar E, Adiguzel E, Kesikburun S, Yenihayat I, Yilmaz B, Alaca R, Tan AK. Assessment of forearm muscle spasticity with sonoelastography in patients with stroke. Br J Radiol. 2016 Dec;89(1068):20160603. doi: 10.1259/bjr.20160603. Epub 2016 Oct 25.
- Jia G, Ma J, Wang S, Wu D, Tan B, Yin Y, Jia L, Cheng L. Long-term Effects of Extracorporeal Shock Wave Therapy on Poststroke Spasticity: A Meta-analysis of Randomized Controlled Trials. J Stroke Cerebrovasc Dis. 2020 Mar;29(3):104591. doi: 10.1016/j.jstrokecerebrovasdis.2019.104591. Epub 2019 Dec 31.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Neurologische Manifestationen
- Erkrankungen des Bewegungsapparates
- Zerebrovaskuläre Erkrankungen
- Erkrankungen des Gehirns
- Erkrankungen des zentralen Nervensystems
- Erkrankungen des Nervensystems
- Gefäßerkrankungen
- Herz-Kreislauf-Erkrankungen
- Muskelerkrankungen
- Muskelhypertonie
- Neuromuskuläre Manifestationen
- Pathologische Zustände, Anzeichen und Symptome
- Anzeichen und Symptome
- Muskelspastik
- Streicheln
- Therapeutika
- Physiotherapiemodalitäten
- Rehabilitation
- Ultraschalltherapie
- Diathermie
- Hyperthermie, induziert
- Extrakorporale Schockwellen -Therapie
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 202309126RIND
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .